Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This systematic review and meta-analysis confirms the triglyceride lowering effects of omega-3 PUFAs, demonstrates potential dose-response effects and shows improvements in thrombogenesis. Omega-3 PUFAs raise LDL levels without concomitant changes in lipid particle size. Changes seen in conventional risk factors are insufficient to explain the cardiovascular disease risk reductions suggested to occur with omega-3 PUFAs. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. cardiovascular disease, docosahexaenoic acid, eicosapentaenoic acid, omega-3 polyunsaturated fatty acids, type 2 diabetes.

Original publication




Journal article


Current Opinion in Lipidology

Publication Date





30 - 38